Stem Cell Therapy International, Inc.
(Public, OTC:SCII) Watch this stockFind more results for
SCII
Advertisement
Key stats and ratios
| Q2 (Jun '09) | 2009 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -8.86% | -434.48% |
| Return on average equity | - | - |
| Employees | 2 | - |
Address
Website links
Stem Cell Therapy International, Inc. discussions
View all discussions »Description
Stem Cell Therapy International, Inc. is a development-stage company. The Company is engaged in the licensing of stem cell technology, the sale of stem cell products, and the referral of patients to affiliated stem cell clinics through its wholly-owned subsidiary Stem Cell Therapy International Corp. (Stem Cell Florida). In April 2009, the Company formed AmStem International, Inc., a wholly owned subsidiary of the Company. Its subsidiaries include Stem Cell Therapy International Corp. and AmStem International, Inc.
Officers and directors
| David Stark | President | |
| Andrew J. Norstrud | Chief Financial Officer, Director | |
| Lixian Jiang | Chief Operating Officer, Patent Trademark Counsel, Director |